Prospektive Bewertung der alleinigen brusterhaltenden Operation bei duktalem Carcinoma in situ (DCIS) mit niedrigem Risiko (ELISA)
Prospektive Bewertung der brusterhaltenden Operation allein bei risikoarmem Duktalkarzinom in situ, definiert durch einen molekularen Expressionsassay in Kombination mit klinisch-pathologischen Merkmalen
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
A prospective cohort study, conducted in Canada, to prospectively evaluate whether the combination of clinicopathological criteria and the Oncotype DX DCIS score can identify a group of women at very low risk of local recurrence following breast conserving surgery who do not require breast radiation therapy. We plan to screen 809 consenting women who will have their tumour tissue specimen sent to Exact Sciences to assess their DCIS score. We anticipate that 526 women will have an Oncotype DX DCIS score with a predicted 10-year risk of local recurrence ≤10%, these women will be enrolled and followed as part of the study.
At each centre, all patients with DCIS referred to radiation oncology will be documented. When a physician identifies an eligible patient, the patient will be approached by the referring physician or delegate to voluntarily provide informed consent to participate in this study. Consenting patients will be registered through the Ontario Clinical Oncology Group's (OCOG) web-based registration system. A two-step registration/enrollment process will be implemented.
Data related to the patient demographics, surgery details, tumour characteristics and ECOG performance will be collected. The patient's tumour specimen will be sent for analysis to Exact Sciences. The DCIS score results will be sent to the referring physician. OCOG will also receive the DCIS score results. Patients will be followed yearly up to 10 years. Bilateral mammograms and breast exams will be performed annually. The study data will be verified by source documentation.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, Kanada, V2S 0C2
- BC Cancer - Abbotsford Centre
-
Prince George, British Columbia, Kanada, V2M 7E9
- BC Cancer - Centre for the North (Prince George)
-
Surrey, British Columbia, Kanada, V3V 1Z2
- BC Cancer - Fraser Valley Centre
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- BC Cancer - Vancouver Centre
-
Victoria, British Columbia, Kanada, V8R 6V5
- BC Cancer - Victoria
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 1V7
- QE II HSC - Nova Scotia Cancer Centre
-
Sydney, Nova Scotia, Kanada, B1P 1P3
- Cape Breton Cancer Centre
-
-
Ontario
-
Barrie, Ontario, Kanada, L4M 6M2
- Royal Victoria Regional Health Centre
-
Hamilton, Ontario, Kanada, L8V 5C2
- Juravinski Cancer Centre
-
London, Ontario, Kanada, N6A 4L6
- London Regional Cancer Program
-
Thunder Bay, Ontario, Kanada, P7B 6V4
- Regional Cancer Care, Thunder Bay Regional Health Sciences Centre
-
Toronto, Ontario, Kanada, M4N 3M5
- Sunnybrook Health Science Centre -Odette Cancer Centre
-
Toronto, Ontario, Kanada, M5G 2M9
- University Health Network - Princess Margaret Cancer Centre
-
Windsor, Ontario, Kanada, N8W 2X3
- Windsor Regional Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, Kanada, J4V 2H1
- Hôpital Charles Le Moyne (CISSS de la Montérégie-Centre)
-
Montreal, Quebec, Kanada, H4A 3J1
- McGill University Health Centre
-
Montreal, Quebec, Kanada, H2L 4M1
- CHUM - Centre Hospitalier de L'Université de Montréal
-
Québec, Quebec, Kanada, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec - Université Laval
-
Trois-Rivières, Quebec, Kanada, G8Z 3R9
- Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie- Centre-du-Québec (CIUSSS MCQ) - Trois-Rivières
-
-
Saskatchewan
-
Regina, Saskatchewan, Kanada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Kanada, S7N4H4
- Saskatoon Cancer Centre
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Prospective cohort study conducted in Canada in women with a low risk DCIS following breast conserving surgery who are candidates for radiation.
Eligibility status should be confirmed by the referring physician or delegate prior to enrollment. It is important that no exceptions are made to the eligibility criteria. Questions related to eligibility requirements and/or specific criteria should be addressed with OCOG prior to enrollment
Beschreibung
Inclusion Criteria:
-
Female patient > 45 years of age with DCIS without microinvasion.
-
Tumour size ≤ 2.5cm.
-
Treated by BCS with clear resection margins ≥ 2 mm or no residual disease on re-excision.*
* Patients with anterior margins and posterior margins ≥1 mm are eligible. Or if the dissection was confirmed to be taken to skin and down to fascia with no DCIS present at inked margins.
-
Oncotype DX DCIS score with a predicted 10-year risk of LR ≤10%.
Exclusion Criteria:
- Multifocal DCIS.
- History of any invasive breast cancer or non-invasive breast cancer in the ipsilateral breast.
- Synchronous or previous invasive or non-invasive breast cancer.
- Prior history of invasive cancer within the last 5 years, excluding non-melanoma skin cancers.
- ECOG performance status ≥3.
- Life expectancy <10 years.
- Geographic inaccessibility for follow-up.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
Single Arm Cohort
Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Ipsilateral local recurrence (LR)
Zeitfenster: 5 Year
|
Defined as recurrent invasive or in situ cancer in the ipsilateral breast |
5 Year
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Ipsilateral invasive local recurrence
Zeitfenster: 5 Year
|
defined as time from study registration to time of recurrent invasive cancer in the ipsilateral breast |
5 Year
|
|
Breast cancer recurrence-free interval (RFI)
Zeitfenster: 5 Year
|
defined as time from study registration to time of documented recurrent disease (ipsilateral breast (DCIS or invasive), regional, distant or death from breast cancer |
5 Year
|
|
Distant disease-free survival (DDFS)
Zeitfenster: 5 Year
|
defined as time from study registration to distant recurrence |
5 Year
|
|
Disease-free survival (DFS)
Zeitfenster: 5 Year
|
defined as time from registration to time of LR (DCIS or invasive), regional and distant recurrence, contralateral breast cancer, new primary (non-breast) and death from any cause |
5 Year
|
|
Overall survival (OS)
Zeitfenster: 5 Year
|
defined as time from registration to death of any cause |
5 Year
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Eileen Rakovitch, M.D., Sunnybrook Research Institute, Sunnybrook Health Science
- Hauptermittler: Tim Whelan, M.D, Juravinski Cancer Centre
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- OCOG-2021-ELISA
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .